Artwork

Contenu fourni par IMPACT Medicom. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par IMPACT Medicom ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Player FM - Application Podcast
Mettez-vous hors ligne avec l'application Player FM !

Emerging Treatments for Advanced, Unresectable Biliary Tract Cancer

14:56
 
Partager
 

Manage episode 343343856 series 2812899
Contenu fourni par IMPACT Medicom. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par IMPACT Medicom ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada.
Our Guest:
Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia.
This podcast episode was sponsored by AstraZeneca Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

  continue reading

68 episodes

Artwork
iconPartager
 
Manage episode 343343856 series 2812899
Contenu fourni par IMPACT Medicom. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par IMPACT Medicom ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.

In this episode we discuss current and emerging systemic treatments for advanced, unresectable biliary tract cancers, as well as the barriers to accessing new treatments in Canada.
Our Guest:
Dr. Howard Lim is a Medical Oncologist, specializing in the treatment of gastrointestinal cancers at the BC Cancer Agency in Vancouver and Clinical Associate Professor in the Faculty of Medicine at the University of British Columbia.
This podcast episode was sponsored by AstraZeneca Canada.

If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com

  continue reading

68 episodes

כל הפרקים

×
 
In this podcast episode, Dr. Versha Banerji, a Canadian hematologist from Manitoba and Dr. Jennifer Brown, an internationally renowned hematologist from the United States, discuss data on the treatment of CLL presented at the American Society of Hematology (or ASH) meeting in San Diego, CA. The discussion involves an analysis of the data from 8 presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada. Our Guests: Dr. Versha Banerji is a hematologist at Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba. Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. This podcast episode was sponsored by BeiGene Canada ULC. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com ( https://www.impactmedicom.com/ ).…
 
In this podcast episode, Dr. Versha Banerji discusses the role of non-covalent BTK inhibitors for the treatment of CLL. Our Guest: Dr. Versha Banerji is a Clinician Scientist at CancerCare Manitoba and Senior Scientist at the Research Institute in Oncology and Hematology, based in Winnipeg, Manitoba. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com This episode was funded by Eli Lilly, Canada.…
 
In this podcast episode, three of Canada’s top hematologists discuss data on the treatment of CLL presented at the European Hematology Association (or EHA) meeting in Madrid, Spain. The discussion involves an analysis of the data from 6 oral presentations on combination and novel therapies for the treatment of CLL. In this discussion, the data is put into the Canadian context, with key take-aways that are relevant to practice in Canada. Our Guests: Dr. Versha Banerji from Max Rady College of Medicine at the University of Manitoba in Winnipeg, Manitoba chairs the meeting. Dr. Banerji is joined by Dr Sarit Assouline, from the Jewish General Hospital in Montreal, Quebec and Dr. Christopher Hillis, from McMaster University in Hamilton, Ontario. If you enjoyed our podcast episode, please review and subscribe. For other medical education content, visit our website at: https://www.impactmedicom.com ( https://www.impactmedicom.com/ )…
 
In this episode of our podcast, recorded at the European Hematology Association (EHA) meeting in Madrid, Spain, we discuss updated results of the BGB-11417-101 trial with Dr. Stephen Opat. The BGB-11417-101 trial examined the efficacy and safety of sonrotoclax plus zanubrutinib for the treatment of R/R CLL. Our Guest: Dr. Stephen Opat is the director of Clinical Haematology at Monash Health, founder and chair of the Australasian Lymphoma and Related Diseases Registry and lead investigator of the Melbourne Genomics Health Alliance Lymphoma Flagship. This podcast episode was sponsored by BeiGene Canada ULC. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
In this episode, Dr. Barbara Melosky discusses cutting edge approaches to the treatment of Lung Cancer, including the use of artificial intelligence and novel therapeutic approaches such as cancer vaccines and new targeted therapies. Our Guest: Dr. Barbara Melosky Dr Melosky is a Professor of Medicine at the University of British Columbia and a Medical Oncologist in Vancouver at BC Cancer. Dr. Melosky specializes in the field of thoracic malignancy. She sits on the Executive Lung Site Committee for CCTG Canadian Clinical Trials Group and is creator and chair of the British Columbia Lung Cancer Biobank. This podcast episode was sponsored by Sanofi Aventis Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
Welcome to our podcast episode on diagnostic, prognostic and predictive biomarkers for the treatment of upper GI cancers. In this episode, Dr Brezden-Masley (medical oncologist) and Dr Streutker (pathologist) discuss the latest biomarkers that may inform treatment of upper GI cancer. Our Guests: Dr. Christine Brezden-Masley Dr. Brezden-Masley is a Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital as well as the Medical Director of Cancer Program for Sinai Health System in Toronto, Canada. Dr. Catherine Streutker Dr. Streutker is a Professor in the Department of Laboratory Medicine & Pathobiology at the University of Toronto. This podcast episode was sponsored by Merck Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
In this podcast episode, Dr. Evan Lipson discusses the use of immunotherapy for patients with skin cancer who have had a kidney transplant. Our guest: Dr. Lipson is an internationally-recognized skin cancer and immunotherapy specialist at Johns Hopkins. Dr. Lipson leads cutting edge clinical trials for patients with melanoma and other skin cancers. As a member of the Johns Hopkins Melanoma and Cancer Immunology Programs, he focuses on evaluating novel therapies for patients with high-risk or advanced disease. Note: The faculty for this program had full editorial control of the content. The following program was funded by Sanofi. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
In this video capsule, Dr. Mark Taylor discusses the surgical implications for the treatment of cSCC. This podcast episode is best viewed alongside the slides, which can be found in the video capsule version: https://www.youtube.com/watch?v=uk5JEUjbkDE&t=127s . Our Guest: Dr. S. Mark Taylor is a Facial Plastic and Reconstructive surgeon in Halifax, Nova Scotia. He is currently a Professor of Surgery at Dalhousie University. His expertise and clinical interest includes rhinoplasty/nasal surgery, eyelid surgery, management of facial paralysis, facial skin cancer, facial reconstruction, and surgery of the aging face. Note: The faculty for this program had full editorial control of the content. The following program was funded by Sanofi. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing the product always refer to the latest Product Monograph, available at www.Sanofi.ca. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
In this podcast episode, Dr. Rami Kotb and Dr. Donna Reece discuss results of the CMRG Isa-CYBORD trial presented at the ASH 2023 meeting, and the implications of the results for Canadian clinical practice. Our Guests: Dr. Rami Kotb is a physician in the Division of Hematology, Department of Medical Oncology & Hematology at CancerCare Manitoba, Winnipeg, MB, Canada Dr Donna Reece is the Director and a Professor of Medicine in the Program for Multiple Myeloma and Related Diseases at the University Health Network. She is also a Professor of Medicine at the University of Toronto and Princess Margaret Hospital in Toronto, ON, Canada Note: A link to the abstract at ASH can be found here: https://ash.confex.com/ash/2023/webprogram/Paper190168.html This podcast episode was sponsored by Sanofi-Aventis Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
In this episode of our podcast, recorded at the American Society of Hematology (ASH) in San Diego, California, we discuss updated results of the ALPINE trial with Dr. Jennifer Brown. The ALPINE trial examined the efficacy and safety of zanubrutinib versus ibrutinib for the treatment of CLL. Our Guest: Dr. Jennifer Brown is the Director of the CLL Center of the Division of Hematologic Malignancies at Dana-Farber Cancer Institute and Professor of Medicine in the Field of Hematologic Oncology at Harvard Medical School in Boston, Massachusetts. Note: The ALPINE trial is published in the New England Journal of Medicine: https://www.nejm.org/doi/full/10.1056/NEJMoa2211582. This podcast episode was sponsored by BeiGene Canada ULC. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com…
 
In this video capsule series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This fifth episode of the series was recorded live from ESMO 2023 with Dr. Thomas Powles, who presented results of the EV-302 trial, and Dr. Normand Blais, Dr. Srikala Sridhar, and Dr. Bernie Eigl, who discussed the impact of new data from trials on 1L LA/mUC . Our Guests: Dr. Thomas Powles: Dr Thomas Powles is a Professor of Genitourinary Oncology and Director of the Barts Cancer Centre at St. Bartholomew's Hospital. He is also the Lead for Solid Tumour Research in London, England. Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis. Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. Dr. Bernie Eigl: Dr. Eigl is a medical oncologist specializing in genitourinary oncology, with a special research interest in bladder and prostate cancers at BC Cancer. He ia alo a Clinical Associate Professor at the University of British Columbia. This podcast episode was sponsored by Seagen Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com .…
 
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto. In this fourth and final episode taken from the webinar, Drs Normand Blais, Terence Friedlander, and Srikala Sridhar provide their perspective on the management of the first-line treatment locally advanced metastatic urothelial carcinoma, including a discussion of the optimal use of enfortumab vedotin plus pembrolizumab and management of associated adverse events. Our Guests: Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis. Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases. Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com .…
 
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto. In this third episode taken from the webinar, Dr. Srikala Sridhar presents a clinical case on the treatment of locally advanced metastatic urothelial carcinoma, highlighting the role of enfortumab vedotin plus pembrolizumab in the treatment plan. Our Guests: Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis. Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases. Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com .…
 
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto. In this second episode taken from the webinar, Dr. Terrence Friedlander presents clinical data in the first-line setting and provides a US perspective on how he manages the treatment of locally advanced metastatic urothelial carcinoma. Our Guests: Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis. Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases. Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. This podcast episode was sponsored by Seagen Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com .…
 
In this podcast series, we discuss the first-line treatment strategies for the management of locally advanced metastatic urothelial carcinoma in Canada. This second part of the series is based on a live webinar presented on September 12th, 2023 by Dr. Normand Blais from the CHUM Cancer center in Montreal, Dr. Terence Friedlander from the Zuckerberg San Francisco General Hospital, and Dr. Srikala Sridhar from the Princess Margaret Cancer Center in Toronto. In this first episode taken from the webinar, Dr. Normand Blais introduces the speakers and discusses the unmet needs of patients with locally advanced metastatic urothelial carcinoma in Canada. Our Guests: Dr. Normand Blais: Dr Blais is the co-founder of the Groupe d’Études en Oncologie du Québec & chair of the Thoracic Oncology Program of the CHUM Cancer center in Montreal. He is the president of Association des hémato-oncologues du Québec. He is interested in lung cancer – clinical trials & correlative science. His clinical research expertise is in lung & bladder cancer, and cancer associated thrombosis. Dr. Terence Friedlander: Dr Friedlander is a clinical & translational medical oncologist with a focus on urologic cancers, specifically cancers of the bladder and prostate. He serves as chief of the ZSFG Division of Hematology & Oncology, & his research is focused on understanding the basic biology of urologic malignancies & on developing novel therapeutic ways to treat diseases. Dr. Srikala Sridhar: Dr Sridhar is a professor in the Department of Medicine at the University of Toronto & a Genitourinary Medical Oncologist & GU Site Lead at the Princess Margaret Cancer Center. She is chair of the Genitourinary Medical Oncologists of Canada & vice chair of the Medical Advisory Board of Bladder Cancer Canada. She has a particular focus on advanced urothelial cancers. The full webinar can be found on our website at: https://www.impactmedicom.com/video-capsules. This podcast episode was sponsored by Seagen Canada. If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com .…
 
Loading …

Bienvenue sur Lecteur FM!

Lecteur FM recherche sur Internet des podcasts de haute qualité que vous pourrez apprécier dès maintenant. C'est la meilleure application de podcast et fonctionne sur Android, iPhone et le Web. Inscrivez-vous pour synchroniser les abonnements sur tous les appareils.

 

icon Daily Deals
icon Daily Deals

Guide de référence rapide

Écoutez cette émission pendant que vous explorez
Lire